PATENT CLAIM ANALYSIS

Application Number: 16310918
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["546", "193000"]

Abstract:
The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A-II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a and R4aa and R4b are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

Claim (Index 4):
The compound according to  claim 3 , or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R4a represents hydrogen, methyl, ethyl, amino, \u2014CH 2 CH 2 CN, \u2014CH 2 CH 2 -morpholinyl or \u2014CH 2 CH 2 OH; and R4b represents hydrogen.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 2.11429
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15580008', '15545149', '13145323', '14552853', '14216486']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8155245672086656
- 35 USC 102 Novelty (BERT): 0.5397302143570121
- Combined Prediction Score: 0.7879451319235002
- Mean Citation Score: 361.492284
- Max Citation Score: 388.39368
- Similarity Product: 290.40145905047893

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test